Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism

Daniel Gillett, Russell Senanayake, James MacFarlane, Waiel Bashari, August Palma, Lihua Hu, Ines Harper, Iosif A. Mendichovszky, Gunnar Antoni, Per Hellman, Anders Sundin, Matthew Hird, István Boros, Morris J. Brown, Heok Cheow, Luigi Aloj, Franklin Aigbirhio and Mark Gurnell
Journal of Nuclear Medicine March 2025, 66 (3) 434-440; DOI: https://doi.org/10.2967/jnumed.124.268425
Daniel Gillett
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
2Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell Senanayake
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James MacFarlane
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Waiel Bashari
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
August Palma
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihua Hu
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ines Harper
2Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iosif A. Mendichovszky
2Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom;
3Department of Radiology, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnar Antoni
4Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Hellman
5Department of Surgical Sciences, Uppsala University, Uppsala, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Sundin
5Department of Surgical Sciences, Uppsala University, Uppsala, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Hird
6Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
István Boros
7Radiopharmaceutical Unit, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morris J. Brown
8Department of Endocrinology, Queen Mary University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heok Cheow
2Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luigi Aloj
2Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom;
3Department of Radiology, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franklin Aigbirhio
6Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom;
7Radiopharmaceutical Unit, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Gurnell
1Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (3)
Journal of Nuclear Medicine
Vol. 66, Issue 3
March 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism
Daniel Gillett, Russell Senanayake, James MacFarlane, Waiel Bashari, August Palma, Lihua Hu, Ines Harper, Iosif A. Mendichovszky, Gunnar Antoni, Per Hellman, Anders Sundin, Matthew Hird, István Boros, Morris J. Brown, Heok Cheow, Luigi Aloj, Franklin Aigbirhio, Mark Gurnell
Journal of Nuclear Medicine Mar 2025, 66 (3) 434-440; DOI: 10.2967/jnumed.124.268425

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[18F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism
Daniel Gillett, Russell Senanayake, James MacFarlane, Waiel Bashari, August Palma, Lihua Hu, Ines Harper, Iosif A. Mendichovszky, Gunnar Antoni, Per Hellman, Anders Sundin, Matthew Hird, István Boros, Morris J. Brown, Heok Cheow, Luigi Aloj, Franklin Aigbirhio, Mark Gurnell
Journal of Nuclear Medicine Mar 2025, 66 (3) 434-440; DOI: 10.2967/jnumed.124.268425
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

Keywords

  • primary aldosteronism
  • PET
  • Molecular imaging
  • [18F]CETO
SNMMI

© 2025 SNMMI

Powered by HighWire